Open Payments

Childrens Mercy Hospital

Type
Teaching hospital
Where
KANSAS CITY, MO
Medicare CCN
263302
Received
$2,671,729 in 1,133 records, 2024 ($213,633 general, $2,458,095 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2024General payment36$213,633
2024Research payment1,097$2,458,095

By company

CompanyRecordsAmountYears
VERTEX PHARMACEUTICALS INCORPORATED9$342,1782024
Ultragenyx Pharmaceutical Inc.78$300,1812024
Edwards Lifesciences Corporation92$207,9832024
BioFire Diagnostics, LLC28$166,5602024
Merck Sharp & Dohme LLC8$158,2892024
Amgen Inc.10$149,0222024
ALBIREO PHARMA, INC.32$147,9342024
Gen-Probe, Inc.8$122,9452024
ACADIA Pharmaceuticals Inc13$121,3122024
OrthoPediatrics Corp.3$90,0002024
Immedica Pharma US, Inc.13$85,0372024
Novo Nordisk AS636$72,5262024
Janssen Research & Development, LLC1$63,6002024
PFIZER INC.16$58,1332024
Hyperfine Operations, Inc.1$42,0102024
Rhythm Pharmaceuticals, Inc.34$38,8332024
Travere Therapeutics, Inc.26$38,0322024
Bayer Healthcare Pharmaceuticals Inc.6$35,4302024
SANOFI US SERVICES INC.8$35,4222024
Hoffmann-La Roche Limited9$32,6882024
Medtronic, Inc.6$31,1782024
QOL Medical, LLC4$31,0832024
Genentech, Inc.5$28,3252024
Dexcom, Inc.7$27,8392024
JAZZ PHARMACEUTICALS INC.2$27,0002024
GENZYME CORPORATION2$23,3962024
QIAGEN, LLC2$23,3932024
Gilead Sciences, Inc.10$20,1022024
Stryker Corporation3$19,7172024
Abbott Laboratories2$13,8362024
IBSA Institut Biochimique SA5$11,8472024
AstraZeneca UK Limited1$10,3622024
Eli Lilly and Company5$9,9052024
ABBVIE INC.2$9,7932024
National Marrow Donor Program4$9,6502024
Alexion Pharmaceuticals, Inc.2$8,8882024
New York Blood Center, Inc.1$8,6402024
Takeda Pharmaceuticals U.S.A., Inc.2$8,0002024
ZOLL Medical Corporation2$5,5002024
Biogen, Inc.1$4,5642024
AKEBIA THERAPEUTICS INC3$4,3302024
PENTAX of America, Inc.3$4,1212024
SANOFI PASTEUR INC.2$3,1002024
Ardelyx, Inc.1$2,8752024
BioMarin Pharmaceutical Inc.1$2,5552024
GE HEALTHCARE2$1,9252024
AMAG Pharmaceuticals, Inc.5$1,7802024
Streck LLC3$1,5452024
Linvatec Corporation1$1,4402024
Draeger Medical Systems, Inc2$1,3002024

By nature of payment

NatureRecordsAmount
Research payment1,097$2,458,095
Grant4$92,813
Compensation for services other than consulting, including serving as faculty or as a speaker at a v8$85,045
Long term medical supply or device loan10$23,034
Space rental or facility fees (teaching hospital only)6$7,900
Consulting Fee5$3,470
Charitable Contribution1$750
Honoraria1$586
Debt forgiveness1$34

Records

DateCompanyAmountNatureFormProductStudyYear
2024-12-31Merck Sharp & Dohme LLC$16,890Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYLIGHTBEAM-U01 Substudy 01B# A Phase 1,2 Substudy to Evaluate the Safety and Efficacy of Pembrolizumab in Combination Wit2024
2024-12-31Stryker Corporation$12,978Long term medical supply or device loanIn-kind items and servicesNA Device, INSTRUMENTS2024
2024-12-31Bayer Healthcare Pharmaceuticals Inc.$5,037Research paymentCash or cash equivalentKerendia Drug, Cardio-renalBAY 948862, A 6-month multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety a2024
2024-12-31Stryker Corporation$4,087Long term medical supply or device loanIn-kind items and servicesRemB Device, INSTRUMENTS2024
2024-12-31Stryker Corporation$2,651Long term medical supply or device loanIn-kind items and servicesRemB Device, INSTRUMENTS2024
2024-12-31Merck Sharp & Dohme LLC$1,485Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYLIGHTBEAM-U01 Substudy 01B# A Phase 1,2 Substudy to Evaluate the Safety and Efficacy of Pembrolizumab in Combination Wit2024
2024-12-31Linvatec Corporation$1,440Long term medical supply or device loanIn-kind items and servicesHANDSTAND Device, ORTHOPEDIC SURGERY2024
2024-12-31Merck Sharp & Dohme LLC$170Research paymentIn-kind items and servicesJANUVIA Drug, ENDOCRINOLOGYA Phase III, Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficac2024
2024-12-31Masimo Corporation$142Long term medical supply or device loanCash or cash equivalentSET and rainbow SET Device, Devices2024
2024-12-31Masimo Corporation$142Long term medical supply or device loanCash or cash equivalentSET and rainbow SET Device, Devices2024
2024-12-31Masimo Corporation$142Long term medical supply or device loanCash or cash equivalentSET and rainbow SET Device, Devices2024
2024-12-31Masimo Corporation$142Long term medical supply or device loanCash or cash equivalentSET and rainbow SET Device, Devices2024
2024-12-31Merck Sharp & Dohme LLC$97Research paymentIn-kind items and services Drug, INFECTIOUS DISEASEA Double-blind, Randomized, Placebo-controlled, Single Ascending Dose Trial to Evaluate the Safety, Tolerability, and Ph2024
2024-12-31Merck Sharp & Dohme LLC$27Research paymentCash or cash equivalentJANUVIA Drug, ENDOCRINOLOGYA Phase III, Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficac2024
2024-12-23Bayer Healthcare Pharmaceuticals Inc.$2,556Research paymentCash or cash equivalentKerendia Drug, Cardio-renalBAY 948862, A 6-month multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety a2024
2024-12-23Eli Lilly and Company$476Research paymentCash or cash equivalentA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF GALCANEZUMAB IN PATIENTS 6 TO 17 YEARS OF AGE WITH EPISODIC MIGR2024
2024-12-20Novo Nordisk AS$5,750Research paymentCash or cash equivalentSogroya Biological, Growth HormoneNN8640-44672024
2024-12-20Novo Nordisk AS$1,080Research paymentCash or cash equivalentAlhemo Drug, HemophiliaNN7415-48072024
2024-12-19ALBIREO PHARMA, INC.$3,850Research paymentCash or cash equivalentBylvay Drug, GastroenterologyAn Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat (A4250) in Children with Biliary A2024
2024-12-19ALBIREO PHARMA, INC.$2,048Research paymentCash or cash equivalentBylvay Drug, GastroenterologyAn Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat (A4250) in Children with Biliary A2024
2024-12-18Ultragenyx Pharmaceutical Inc.$1,541Research paymentCash or cash equivalentUX143-CL3142024
2024-12-18ACADIA Pharmaceuticals Inc$1,522Research paymentCash or cash equivalentACP-101 Drug, HYPERPHAGIA IN PRADER-WILLI SYNDROMEACP-101-3022024
2024-12-17BioFire Diagnostics, LLC$1,000Research paymentIn-kind items and servicesBIOFIRE SPOTFIRE Respiratory/Sore Throat (R/ST) Panel Mini Device, DiagnosticsSpotFire R Mini ANS Prospective Study2024
2024-12-16Gen-Probe, Inc.$9,000Research paymentCash or cash equivalentAPTIMA Device, Diagnostics655-A10960-0012024
2024-12-16Edwards Lifesciences Corporation$8,000Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesCOMPASSION S3 Post Approval Study (2020-07)2024
2024-12-16Edwards Lifesciences Corporation$568Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesCOMPASSION S3 Post Approval Study (2020-07)2024
2024-12-13Catalent Pharma Solutions, LLC$750Charitable ContributionCash or cash equivalent2024
2024-12-12ALBIREO PHARMA, INC.$2,050Research paymentCash or cash equivalentBylvay Drug, GastroenterologyA Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Odevixibat (A4250) in Childr2024
2024-12-12Novo Nordisk AS$13Research paymentIn-kind items and servicesAlhemo Drug, HemophiliaNN7415-46162024
2024-12-12Novo Nordisk AS$13Research paymentIn-kind items and servicesAlhemo Drug, HemophiliaNN7415-46162024
2024-12-12Novo Nordisk AS$13Research paymentIn-kind items and servicesAlhemo Drug, HemophiliaNN7415-46162024
2024-12-12Novo Nordisk AS$13Research paymentIn-kind items and servicesAlhemo Drug, HemophiliaNN7415-46162024
2024-12-12Novo Nordisk AS$13Research paymentIn-kind items and servicesAlhemo Drug, HemophiliaNN7415-46162024
2024-12-12Novo Nordisk AS$13Research paymentIn-kind items and servicesAlhemo Drug, HemophiliaNN7415-46162024
2024-12-12Novo Nordisk AS$13Research paymentIn-kind items and servicesAlhemo Drug, HemophiliaNN7415-46162024
2024-12-12Novo Nordisk AS$13Research paymentIn-kind items and servicesAlhemo Drug, HemophiliaNN7415-46162024
2024-12-12Novo Nordisk AS$13Research paymentIn-kind items and servicesAlhemo Drug, HemophiliaNN7415-46162024
2024-12-12Novo Nordisk AS$13Research paymentIn-kind items and servicesAlhemo Drug, HemophiliaNN7415-46162024
2024-12-12Novo Nordisk AS$13Research paymentIn-kind items and servicesAlhemo Drug, HemophiliaNN7415-46162024
2024-12-11ACADIA Pharmaceuticals Inc$27,666Research paymentCash or cash equivalentACP-101 Drug, HYPERPHAGIA IN PRADER-WILLI SYNDROMEACP-101-3022024
2024-12-11ACADIA Pharmaceuticals Inc$2,496Research paymentCash or cash equivalentACP-101 Drug, HYPERPHAGIA IN PRADER-WILLI SYNDROMEACP-101-3032024
2024-12-10Dexcom, Inc.$9,550Research paymentCash or cash equivalentDEXCOM G7 GSS (161) Medical Supply, EndocrinologyPOST APPROVAL STUDY FOR NON-ADJUNCTIVE USE OF DEXCOM G5 AND G6 CGM SYSTEM FOR DIABETES MANAGEMENT (COACH)2024
2024-12-10Ultragenyx Pharmaceutical Inc.$6,057Research paymentCash or cash equivalentUX143-CL3012024
2024-12-06BioFire Diagnostics, LLC$33,706Research paymentCash or cash equivalentBIOFIRE SPOTFIRE Respiratory/Sore Throat (R/ST) Panel Mini Device, DiagnosticsSpotFire R Mini ANS Prospective Study2024
2024-12-06Gen-Probe, Inc.$9,100Research paymentCash or cash equivalentAPTIMA Device, Diagnostics655-A10960-0012024
2024-12-05ALBIREO PHARMA, INC.$75Research paymentCash or cash equivalentBylvay Drug, GastroenterologyAn Open Label Study to Evaluate the Long-term Safety and Efficacy of Odevixibat (A4250) in Patients With Alagille Syndro2024
2024-12-04Immedica Pharma US, Inc.$11,167Research paymentCash or cash equivalentA Phase 3, Open-label Study of Adjunctive Ganaxolone (GNX) Treatment in Children and Adults With Tuberous Sclerosis Comp2024
2024-12-03Ultragenyx Pharmaceutical Inc.$2,351Research paymentCash or cash equivalentUX143-CL3142024
2024-12-03Ultragenyx Pharmaceutical Inc.$1,624Research paymentCash or cash equivalentUX143-CL3012024
2024-12-03Medtronic, Inc.$1,500Research paymentCash or cash equivalentINVOS Device, Cerebral/Somatic OximetryINVOS CathLab2024
2024-12-01BioMarin Pharmaceutical Inc.$2,555Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentVOXZOGO 1.2mg Drug, Achondroplasia2024
2024-11-27GE HEALTHCARE$1,225Consulting FeeCash or cash equivalent2024
2024-11-27GE HEALTHCARE$700Consulting FeeCash or cash equivalent2024
2024-11-26Ultragenyx Pharmaceutical Inc.$9,684Research paymentCash or cash equivalentUX143-CL3012024
2024-11-26Amgen Inc.$3,600Research paymentCash or cash equivalentKyprolis Drug, OncologyKyprolis CFZ Ph1/2 Pediatric ALL2024
2024-11-26Immedica Pharma US, Inc.$1,500Research paymentCash or cash equivalentA Phase 3, Open-label Study of Adjunctive Ganaxolone (GNX) Treatment in Children and Adults With Tuberous Sclerosis Comp2024
2024-11-26Draeger Medical Systems, Inc$700Space rental or facility fees (teaching hospital only)Cash or cash equivalentBabylog VN800 Device, Pulmonary/Respiratory Diseases2024
2024-11-20Novo Nordisk AS$1,080Research paymentCash or cash equivalentAlhemo Drug, HemophiliaNN7415-48072024
2024-11-19Ultragenyx Pharmaceutical Inc.$3,082Research paymentCash or cash equivalentUX143-CL3142024
2024-11-19AMAG Pharmaceuticals, Inc.$40Research paymentCash or cash equivalentFERAHEME Drug, For the treatment of iron deficiency anemia associated with chronic kidney diseaseA PHASE 3, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY (COMPARED TO IRON SUCROSE), EFFICACY AND PHA2024
2024-11-14Edwards Lifesciences Corporation$5,600Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesCOMPASSION S3 Post Approval Study (2020-07)2024
2024-11-14Edwards Lifesciences Corporation$177Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesCOMPASSION S3 Post Approval Study (2020-07)2024
2024-11-14Novo Nordisk AS$7Research paymentIn-kind items and servicesAlhemo Drug, HemophiliaNN7415-46162024
2024-11-14Novo Nordisk AS$7Research paymentIn-kind items and servicesAlhemo Drug, HemophiliaNN7415-46162024
2024-11-14Novo Nordisk AS$7Research paymentIn-kind items and servicesAlhemo Drug, HemophiliaNN7415-46162024
2024-11-14Novo Nordisk AS$7Research paymentIn-kind items and servicesAlhemo Drug, HemophiliaNN7415-46162024
2024-11-14Novo Nordisk AS$7Research paymentIn-kind items and servicesAlhemo Drug, HemophiliaNN7415-46162024
2024-11-14Novo Nordisk AS$7Research paymentIn-kind items and servicesAlhemo Drug, HemophiliaNN7415-46162024
2024-11-14Novo Nordisk AS$7Research paymentIn-kind items and servicesAlhemo Drug, HemophiliaNN7415-46162024
2024-11-14Novo Nordisk AS$7Research paymentIn-kind items and servicesAlhemo Drug, HemophiliaNN7415-46162024
2024-11-14Novo Nordisk AS$7Research paymentIn-kind items and servicesAlhemo Drug, HemophiliaNN7415-46162024
2024-11-14Novo Nordisk AS$7Research paymentIn-kind items and servicesAlhemo Drug, HemophiliaNN7415-46162024
2024-11-14Novo Nordisk AS$7Research paymentIn-kind items and servicesAlhemo Drug, HemophiliaNN7415-46162024
2024-11-14Novo Nordisk AS$7Research paymentIn-kind items and servicesAlhemo Drug, HemophiliaNN7415-46162024
2024-11-14Novo Nordisk AS$7Research paymentIn-kind items and servicesAlhemo Drug, HemophiliaNN7415-46162024
2024-11-14Novo Nordisk AS$7Research paymentIn-kind items and servicesAlhemo Drug, HemophiliaNN7415-46162024
2024-11-14Novo Nordisk AS$7Research paymentIn-kind items and servicesAlhemo Drug, HemophiliaNN7415-46162024
2024-11-14Novo Nordisk AS$7Research paymentIn-kind items and servicesAlhemo Drug, HemophiliaNN7415-46162024
2024-11-14Novo Nordisk AS$7Research paymentIn-kind items and servicesAlhemo Drug, HemophiliaNN7415-46162024
2024-11-14Novo Nordisk AS$7Research paymentIn-kind items and servicesAlhemo Drug, HemophiliaNN7415-46162024
2024-11-14Novo Nordisk AS$7Research paymentIn-kind items and servicesAlhemo Drug, HemophiliaNN7415-46162024
2024-11-14Novo Nordisk AS$7Research paymentIn-kind items and servicesAlhemo Drug, HemophiliaNN7415-46162024
2024-11-14Novo Nordisk AS$7Research paymentIn-kind items and servicesAlhemo Drug, HemophiliaNN7415-46162024
2024-11-14Novo Nordisk AS$7Research paymentIn-kind items and servicesAlhemo Drug, HemophiliaNN7415-46162024
2024-11-14Novo Nordisk AS$7Research paymentIn-kind items and servicesAlhemo Drug, HemophiliaNN7415-46162024
2024-11-14Novo Nordisk AS$7Research paymentIn-kind items and servicesAlhemo Drug, HemophiliaNN7415-46162024
2024-11-14Novo Nordisk AS$7Research paymentIn-kind items and servicesAlhemo Drug, HemophiliaNN7415-46162024
2024-11-14Novo Nordisk AS$7Research paymentIn-kind items and servicesAlhemo Drug, HemophiliaNN7415-46162024
2024-11-14Novo Nordisk AS$7Research paymentIn-kind items and servicesAlhemo Drug, HemophiliaNN7415-46162024
2024-11-14Novo Nordisk AS$7Research paymentIn-kind items and servicesAlhemo Drug, HemophiliaNN7415-46162024
2024-11-14Novo Nordisk AS$7Research paymentIn-kind items and servicesAlhemo Drug, HemophiliaNN7415-46162024
2024-11-14Novo Nordisk AS$7Research paymentIn-kind items and servicesAlhemo Drug, HemophiliaNN7415-46162024
2024-11-14Novo Nordisk AS$7Research paymentIn-kind items and servicesAlhemo Drug, HemophiliaNN7415-46162024
2024-11-14Novo Nordisk AS$7Research paymentIn-kind items and servicesAlhemo Drug, HemophiliaNN7415-46162024
2024-11-14Novo Nordisk AS$7Research paymentIn-kind items and servicesAlhemo Drug, HemophiliaNN7415-46162024
2024-11-14Novo Nordisk AS$7Research paymentIn-kind items and servicesAlhemo Drug, HemophiliaNN7415-46162024
2024-11-14Novo Nordisk AS$7Research paymentIn-kind items and servicesAlhemo Drug, HemophiliaNN7415-46162024
2024-11-14Novo Nordisk AS$7Research paymentIn-kind items and servicesAlhemo Drug, HemophiliaNN7415-46162024
2024-11-14Novo Nordisk AS$7Research paymentIn-kind items and servicesAlhemo Drug, HemophiliaNN7415-46162024
2024-11-14Novo Nordisk AS$7Research paymentIn-kind items and servicesAlhemo Drug, HemophiliaNN7415-46162024
2024-11-14Novo Nordisk AS$7Research paymentIn-kind items and servicesAlhemo Drug, HemophiliaNN7415-46162024
2024-11-14Novo Nordisk AS$7Research paymentIn-kind items and servicesAlhemo Drug, HemophiliaNN7415-46162024
2024-11-14Novo Nordisk AS$7Research paymentIn-kind items and servicesAlhemo Drug, HemophiliaNN7415-46162024
2024-11-14Novo Nordisk AS$7Research paymentIn-kind items and servicesAlhemo Drug, HemophiliaNN7415-46162024
2024-11-14Novo Nordisk AS$7Research paymentIn-kind items and servicesAlhemo Drug, HemophiliaNN7415-46162024
2024-11-14Novo Nordisk AS$7Research paymentIn-kind items and servicesAlhemo Drug, HemophiliaNN7415-46162024
2024-11-14Novo Nordisk AS$7Research paymentIn-kind items and servicesAlhemo Drug, HemophiliaNN7415-46162024
2024-11-14Novo Nordisk AS$7Research paymentIn-kind items and servicesAlhemo Drug, HemophiliaNN7415-46162024
2024-11-14Novo Nordisk AS$7Research paymentIn-kind items and servicesAlhemo Drug, HemophiliaNN7415-46162024
2024-11-14Novo Nordisk AS$7Research paymentIn-kind items and servicesAlhemo Drug, HemophiliaNN7415-46162024
2024-11-14Novo Nordisk AS$7Research paymentIn-kind items and servicesAlhemo Drug, HemophiliaNN7415-46162024
2024-11-14Novo Nordisk AS$7Research paymentIn-kind items and servicesAlhemo Drug, HemophiliaNN7415-46162024
2024-11-14Novo Nordisk AS$7Research paymentIn-kind items and servicesAlhemo Drug, HemophiliaNN7415-46162024
2024-11-14Novo Nordisk AS$7Research paymentIn-kind items and servicesAlhemo Drug, HemophiliaNN7415-46162024
2024-11-14Novo Nordisk AS$7Research paymentIn-kind items and servicesAlhemo Drug, HemophiliaNN7415-46162024
2024-11-14Novo Nordisk AS$7Research paymentIn-kind items and servicesAlhemo Drug, HemophiliaNN7415-46162024
2024-11-14Novo Nordisk AS$7Research paymentIn-kind items and servicesAlhemo Drug, HemophiliaNN7415-46162024
2024-11-14Novo Nordisk AS$7Research paymentIn-kind items and servicesAlhemo Drug, HemophiliaNN7415-46162024
2024-11-14Novo Nordisk AS$7Research paymentIn-kind items and servicesAlhemo Drug, HemophiliaNN7415-46162024
2024-11-14Novo Nordisk AS$7Research paymentIn-kind items and servicesAlhemo Drug, HemophiliaNN7415-46162024
2024-11-14Novo Nordisk AS$7Research paymentIn-kind items and servicesAlhemo Drug, HemophiliaNN7415-46162024
2024-11-14Novo Nordisk AS$7Research paymentIn-kind items and servicesAlhemo Drug, HemophiliaNN7415-46162024
2024-11-14Novo Nordisk AS$7Research paymentIn-kind items and servicesAlhemo Drug, HemophiliaNN7415-46162024
2024-11-14Novo Nordisk AS$7Research paymentIn-kind items and servicesAlhemo Drug, HemophiliaNN7415-46162024
2024-11-14Novo Nordisk AS$7Research paymentIn-kind items and servicesAlhemo Drug, HemophiliaNN7415-46162024
2024-11-14Novo Nordisk AS$7Research paymentIn-kind items and servicesAlhemo Drug, HemophiliaNN7415-46162024
2024-11-14Novo Nordisk AS$7Research paymentIn-kind items and servicesAlhemo Drug, HemophiliaNN7415-46162024
2024-11-14Novo Nordisk AS$7Research paymentIn-kind items and servicesAlhemo Drug, HemophiliaNN7415-46162024
2024-11-14Novo Nordisk AS$7Research paymentIn-kind items and servicesAlhemo Drug, HemophiliaNN7415-46162024
2024-11-14Novo Nordisk AS$7Research paymentIn-kind items and servicesAlhemo Drug, HemophiliaNN7415-46162024
2024-11-14Novo Nordisk AS$7Research paymentIn-kind items and servicesAlhemo Drug, HemophiliaNN7415-46162024
2024-11-14Novo Nordisk AS$7Research paymentIn-kind items and servicesAlhemo Drug, HemophiliaNN7415-46162024
2024-11-14Novo Nordisk AS$7Research paymentIn-kind items and servicesAlhemo Drug, HemophiliaNN7415-46162024
2024-11-14Novo Nordisk AS$7Research paymentIn-kind items and servicesAlhemo Drug, HemophiliaNN7415-46162024
2024-11-14Novo Nordisk AS$7Research paymentIn-kind items and servicesAlhemo Drug, HemophiliaNN7415-46162024
2024-11-14Novo Nordisk AS$7Research paymentIn-kind items and servicesAlhemo Drug, HemophiliaNN7415-46162024
2024-11-14Novo Nordisk AS$7Research paymentIn-kind items and servicesAlhemo Drug, HemophiliaNN7415-46162024
2024-11-14Novo Nordisk AS$7Research paymentIn-kind items and servicesAlhemo Drug, HemophiliaNN7415-46162024
2024-11-14Novo Nordisk AS$7Research paymentIn-kind items and servicesAlhemo Drug, HemophiliaNN7415-46162024
2024-11-14Novo Nordisk AS$3Research paymentIn-kind items and servicesAlhemo Drug, HemophiliaNN7415-46162024
2024-11-14Novo Nordisk AS$3Research paymentIn-kind items and servicesAlhemo Drug, HemophiliaNN7415-46162024
2024-11-14Novo Nordisk AS$3Research paymentIn-kind items and servicesAlhemo Drug, HemophiliaNN7415-46162024
2024-11-14Novo Nordisk AS$3Research paymentIn-kind items and servicesAlhemo Drug, HemophiliaNN7415-46162024
2024-11-14Novo Nordisk AS$3Research paymentIn-kind items and servicesAlhemo Drug, HemophiliaNN7415-46162024
2024-11-14Novo Nordisk AS$3Research paymentIn-kind items and servicesAlhemo Drug, HemophiliaNN7415-46162024
2024-11-14Novo Nordisk AS$3Research paymentIn-kind items and servicesAlhemo Drug, HemophiliaNN7415-46162024
2024-11-14Novo Nordisk AS$3Research paymentIn-kind items and servicesAlhemo Drug, HemophiliaNN7415-46162024
2024-11-14Novo Nordisk AS$3Research paymentIn-kind items and servicesAlhemo Drug, HemophiliaNN7415-46162024
2024-11-14Novo Nordisk AS$3Research paymentIn-kind items and servicesAlhemo Drug, HemophiliaNN7415-46162024
2024-11-14Novo Nordisk AS$3Research paymentIn-kind items and servicesAlhemo Drug, HemophiliaNN7415-46162024
2024-11-13Medtronic, Inc.$3,699Research paymentCash or cash equivalentINVOS Device, Cerebral/Somatic OximetryINVOS CathLab2024
2024-11-13Travere Therapeutics, Inc.$90Research paymentCash or cash equivalentA Phase 2, Open-Label, Single-Arm, Cohort Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Sparsentan Tre2024
2024-11-12Immedica Pharma US, Inc.$22,600Research paymentCash or cash equivalentA Phase 3, Open-label Study of Adjunctive Ganaxolone (GNX) Treatment in Children and Adults With Tuberous Sclerosis Comp2024
2024-11-12Edwards Lifesciences Corporation$4,590Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesCOMPASSION S3 2015-012024
2024-11-12Immedica Pharma US, Inc.$3,070Research paymentCash or cash equivalentA Phase 3, Open-label Study of Adjunctive Ganaxolone (GNX) Treatment in Children and Adults With Tuberous Sclerosis Comp2024
2024-11-12Ultragenyx Pharmaceutical Inc.$2,351Research paymentCash or cash equivalentUX143-CL3142024
2024-11-12Ultragenyx Pharmaceutical Inc.$2,247Research paymentCash or cash equivalentUX143-CL3012024
2024-11-12AMAG Pharmaceuticals, Inc.$500Research paymentCash or cash equivalentFERAHEME Drug, For the treatment of iron deficiency anemia associated with chronic kidney diseaseA PHASE 3, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY (COMPARED TO IRON SUCROSE), EFFICACY AND PHA2024
2024-11-12Edwards Lifesciences Corporation$284Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesCOMPASSION S3 2015-012024
2024-11-07Bayer Healthcare Pharmaceuticals Inc.$3,102Research paymentCash or cash equivalentKerendia Drug, Cardio-renalBAY 948862, A 6-month multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety a2024
2024-11-07BioFire Diagnostics, LLC$300Research paymentIn-kind items and servicesBIOFIRE SPOTFIRE Respiratory/Sore Throat (R/ST) Panel Mini Device, DiagnosticsSpotFire R Mini ANS Prospective Study2024
2024-11-06Novo Nordisk AS$15,250Research paymentCash or cash equivalentAlhemo Drug, HemophiliaNN7415-46162024
2024-11-06Rhythm Pharmaceuticals, Inc.$1,744Research paymentCash or cash equivalentEMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway2024
2024-11-06Rhythm Pharmaceuticals, Inc.$500Research paymentCash or cash equivalentEMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway2024
2024-11-06Rhythm Pharmaceuticals, Inc.$153Research paymentCash or cash equivalentEMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway2024
2024-11-06Rhythm Pharmaceuticals, Inc.$78Research paymentCash or cash equivalentEMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway2024
2024-11-05Ultragenyx Pharmaceutical Inc.$3,399Research paymentCash or cash equivalentUX143-CL3012024
2024-11-05Gilead Sciences, Inc.$61Research paymentCash or cash equivalentVemlidy Drug, HBVA Phase 2/3 Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Ala2024
2024-11-04Ultragenyx Pharmaceutical Inc.$15,145Research paymentCash or cash equivalentUX143-CL3012024
2024-11-04SANOFI US SERVICES INC.$541Research paymentCash or cash equivalentTZIELD Biological, Endocrine & Metabolic DiseasesA Multicenter, Multinational Extension of Study PRV-031-001 to Evaluate the Long-Term Safety of Teplizumab (PRV-031), a 2024
2024-10-31Novo Nordisk AS$2,388Research paymentCash or cash equivalentSogroya Biological, Growth HormoneNN8640-42632024
2024-10-31Novo Nordisk AS$1,926Research paymentCash or cash equivalentSogroya Biological, Growth HormoneNN8640-44672024
2024-10-30ACADIA Pharmaceuticals Inc$15,539Research paymentCash or cash equivalentACP-101 Drug, HYPERPHAGIA IN PRADER-WILLI SYNDROMEACP-101-3022024
2024-10-30PFIZER INC.$11,471Research paymentCash or cash equivalentLOW INTERVENTIONAL COHORT STUDY OF MYOCARDITISPERICARDITIS ASSOCIATED WITH COMIRNATY IN PERSONS LESS THAN 21 YEARS OF AG2024
2024-10-30PFIZER INC.$3,300Research paymentCash or cash equivalentLOW INTERVENTIONAL COHORT STUDY OF MYOCARDITISPERICARDITIS ASSOCIATED WITH COMIRNATY IN PERSONS LESS THAN 21 YEARS OF AG2024
2024-10-30PFIZER INC.$1,296Research paymentCash or cash equivalentLOW INTERVENTIONAL COHORT STUDY OF MYOCARDITISPERICARDITIS ASSOCIATED WITH COMIRNATY IN PERSONS LESS THAN 21 YEARS OF AG2024
2024-10-30Ultragenyx Pharmaceutical Inc.$1,215Research paymentCash or cash equivalentUX143-CL3012024
2024-10-30Ultragenyx Pharmaceutical Inc.$558Research paymentCash or cash equivalentUX143-CL3012024
2024-10-30Ultragenyx Pharmaceutical Inc.$82Research paymentCash or cash equivalentUX143-CL3012024
2024-10-30Ultragenyx Pharmaceutical Inc.$36Research paymentCash or cash equivalentUX143-CL3012024
2024-10-29Dexcom, Inc.$2,794Research paymentCash or cash equivalentDEXCOM G7 GSS (161) Medical Supply, EndocrinologyPOST APPROVAL STUDY FOR NON-ADJUNCTIVE USE OF DEXCOM G5 AND G6 CGM SYSTEM FOR DIABETES MANAGEMENT (COACH)2024
2024-10-25Hoffmann-La Roche Limited$3,350Research paymentCash or cash equivalentEfficacy Safety of Obinutuzumab vs MMF in patients with idiopathic nephrotic syndrome2024
2024-10-25National Marrow Donor Program$3,125Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2024
2024-10-25Hoffmann-La Roche Limited$2,866Research paymentCash or cash equivalentEfficacy Safety of Obinutuzumab vs MMF in patients with idiopathic nephrotic syndrome2024
2024-10-25Hoffmann-La Roche Limited$1,750Research paymentCash or cash equivalentEfficacy Safety of Obinutuzumab vs MMF in patients with idiopathic nephrotic syndrome2024
2024-10-25Hoffmann-La Roche Limited$750Research paymentCash or cash equivalentEfficacy Safety of Obinutuzumab vs MMF in patients with idiopathic nephrotic syndrome2024
2024-10-25Hoffmann-La Roche Limited$103Research paymentCash or cash equivalentEfficacy Safety of Obinutuzumab vs MMF in patients with idiopathic nephrotic syndrome2024
2024-10-23Rhythm Pharmaceuticals, Inc.$3,252Research paymentCash or cash equivalentEMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway2024
2024-10-23Rhythm Pharmaceuticals, Inc.$3,252Research paymentCash or cash equivalentEMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway2024
2024-10-23Rhythm Pharmaceuticals, Inc.$3,252Research paymentCash or cash equivalentEMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway2024
2024-10-23Rhythm Pharmaceuticals, Inc.$2,929Research paymentCash or cash equivalentEMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway2024
2024-10-23Rhythm Pharmaceuticals, Inc.$2,929Research paymentCash or cash equivalentEMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway2024
2024-10-23Rhythm Pharmaceuticals, Inc.$2,539Research paymentCash or cash equivalentEMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway2024
2024-10-23Rhythm Pharmaceuticals, Inc.$2,539Research paymentCash or cash equivalentEMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway2024
2024-10-22Gilead Sciences, Inc.$2,339Research paymentCash or cash equivalentVemlidy Drug, HBVA Phase 2/3 Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Ala2024
2024-10-18Hoffmann-La Roche Limited$2,866Research paymentCash or cash equivalentEfficacy Safety of Obinutuzumab vs MMF in patients with idiopathic nephrotic syndrome2024
2024-10-18Hoffmann-La Roche Limited$103Research paymentCash or cash equivalentEfficacy Safety of Obinutuzumab vs MMF in patients with idiopathic nephrotic syndrome2024
2024-10-17Edwards Lifesciences Corporation$11,730Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesCOMPASSION S3 2015-012024
2024-10-17ALBIREO PHARMA, INC.$5,776Research paymentCash or cash equivalentBylvay Drug, GastroenterologyA Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Odevixibat (A4250) in Childr2024
2024-10-17Edwards Lifesciences Corporation$5,200Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesCOMPASSION S3 Post Approval Study (2020-07)2024

The latest 200 records of 1,133.

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

Jackson CountyKansas City city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Kansas City, MO, county Jackson County, MO, state Missouri; placed by its city name.

MeasurePlace (city or town)
Kansas City, MO
County
Jackson County, MO
State
Missouri
Population B01003510,612719,9766,191,814
Population, 2020 census P1508,090717,2046,154,913
Median age B0100235.837.039.0
Under 18 B0100122.5%23.3%22.3%
65 and over B0100114.3%15.9%17.9%
Households B11001221,979306,7982,508,227
Foreign born B050028.6%6.6%4.5%
Median household income B19013$69,166$68,577$70,702
Median family income B19113$92,934$90,585$91,360
Per capita income B19301$41,393$39,559$39,695
Poverty rate B1700114.6%14.1%12.6%
Unemployment rate B230254.4%4.7%4.0%
Civilian labor force B23025279,828381,4333,120,639
Mean commute (minutes) B0801321.723.423.5
Bachelor's degree or higher B1500338.4%34.0%32.4%
Housing units B25001245,346336,2882,825,287
Owner-occupied B2500355.4%59.1%68.1%
Renters B2500344.6%40.9%31.9%
Median home value B25077$242,900$230,500$230,300
Median gross rent B25064$1,238$1,197$1,033
White, not Hispanic B0300254.0%59.3%76.3%
Black B0300225.2%22.0%10.9%
Hispanic or Latino B0300212.5%11.4%5.2%
Asian B030022.8%1.8%2.1%
American Indian and Alaska Native B030020.1%0.1%0.2%

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Kansas City, MO.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.